Cytek Biosciences Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Trading Arrangements
During the three months ended June 30, 2024, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule-10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K as set forth in the table below:
| Type of Trading Arrangement | |||||
|---|---|---|---|---|---|
| Name and Position · Action · Adoption/ Termination Date · Rule 10b5-1* · Non- Rule 10b5-1** · Total Shares of Common Stock to be Sold · Expiration Date | |||||
| Ming Yan , Chief Technology Officer and Director | Termination 1 | May 28, 2024 | X | 1,280,000 | February 14, 2025 |
- Contract, instructions, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
1 Represents the termination of a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) adopted on November 30, 2023.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.